Article

Recursion Pharmaceuticals, a small-cap biotech company, operates the largest AI supercomputer in the pharmaceutical industry to accelerate drug development. Despite its innovative approach using a proprietary operating system and AI-powered algorithms to predict effective compounds for diseases, it has no products on the market or in phase 3 trials, making its stock high-risk. In contrast, Eli Lilly has announced plans to construct a larger AI supercomputer, leveraging extensive data from past clinical trials to enhance its drug discovery process, positioning it as a more stable investment compared to Recursion.